JARID1B Antibody

• 产品编号：CST-3273S      品牌：CST       原厂货号：3273S
• 产品分类：抗体 > 一抗 > 蛋白特异性一抗
• 应用分类：

描述：

JARID1B Antibody能够检测内源性JARID1B蛋白水平。该抗体不与其它JARID蛋白发生交叉反应，包括JARID1A、JARID1C和JARID1D。通过合成的与人源JARID1B蛋白相应的多肽片段去免疫动物从而制备出此多克隆抗体。通过蛋白A和多肽亲和层析纯化获得。组蛋白赖氨酸的甲基化水平对于基因组的活化和非活化区域的形成是主要决定因素，并且在发育期间对于基因组的正确进程起着关键作用(1,2)。包含蛋白质的Jumonji C (JmjC)区域代表最大的潜在组蛋白去乙酰化酶蛋白(3)。JmjC区域通过氧化反应能催化单、双和三甲基化的赖氨酸残基的去乙甲基化，这种氧化反应需要铁离子和α-酮戊二酸(3)。基于同源性，人源和小鼠都包含至少30种这样蛋白质，这能够被分为7个不同的家族(3)。JARID (Jumonji/AT-rich interactive domain-containing protein)家族包含四个成员：JARID1A (RBP2 和RBBP2)、JARID1B (PLU-1)、JARID1C (SMCX)和JARID1D (SMCY) (4)。除了JmJC区域之外，这些蛋白质包含JmJN、BRIGHT、C5HC2 zinc-finger和PHD结构域，后者能结合到甲基化的histone H3 (Lys9) (4)。所有四个JARID蛋白都是双甲基化和三甲基化 histone H3蛋白Lys4位点去甲基化； JARID1B蛋白也使单甲基化histone H3蛋白Lys4位点去甲基化(5-7)。JARID1A蛋白是一个关键RB-相互作用蛋白，并且在ES细胞分化期间对Polycomb-Repressive Complex 2 (PRC2)介导的转录抑制是需要的(8)。一个JARID1A-NUP98基因融合是与骨髓性白血病有关联(9)。JARID1B与许多蛋白质包括c-Myc和HDAC4相互作用，这可能通过封闭末端分化在细胞命运决策中起着一定作用(10-12)。JARID1B在许多乳腺癌中过表达，并且可能通过抑制多种肿瘤抑制基因包括BRCA1和HOXA5而发挥作用 (13,14)。JARID1C已经被发现在HDAC1、HDAC2、G9a和REST的复合物中，在非神经细胞中这结合到并且抑制REST靶基因(7)。JARID1C突变是与 X-连锁的智力低下和癫痫有关联(15,16)。JARID1D很大程度上时没有特征的。

1. Kubicek, S. et al. (2006) Ernst Schering Res Found Workshop , 1-27.
2. Lin, W. and Dent, S.Y. (2006) Curr Opin Genet Dev 16, 137-42.
3. Klose, R.J. et al. (2006) Nat Rev Genet 7, 715-27.
4. Benevolenskaya, E.V. (2007) Biochem Cell Biol 85, 435-43.
5. Christensen, J. et al. (2007) Cell 128, 1063-76.
6. Yamane, K. et al. (2007) Mol Cell 25, 801-12.
7. Tahiliani, M. et al. (2007) Nature 447, 601-5.
8. Pasini, D. et al. (2008) Genes Dev 22, 1345-55.
9. van Zutven, L.J. et al. (2006) Genes Chromosomes Cancer 45, 437-46.
10. Secombe, J. et al. (2007) Genes Dev 21, 537-51.
11. Barrett, A. et al. (2007) Int J Cancer 121, 265-75.
12. Dey, B.K. et al. (2008) Mol Cell Biol 28, 5312-27.
13. Barrett, A. et al. (2002) Int J Cancer 101, 581-8.
14. Lu, P.J. et al. (1999) J Biol Chem 274, 15633-45.
15. Tzschach, A. et al. (2006) Hum Mutat 27, 389.
16. Jensen, L.R. et al. (2005) Am J Hum Genet 76, 227-36.

原厂资料：

Specificity / Sensitivity

JARID1B Antibody detects endogenous levels of JARID1B protein. The antibody does not cross-react with other JARID proteins, including JARID1A, JARID1C and JARID1D.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to the human JARID1B protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

The methylation state of lysine residues in histone proteins is a major determinant for formation of active and inactive regions of the genome and is crucial for proper programming of the genome during development (1,2). Jumonji C (JmjC) domain-containing proteins represent the largest class of potential histone demethylase proteins (3). The JmjC domain can catalyze the demethylation of mono-, di-, and tri-methyl lysine residues via an oxidative reaction that requires iron and α-ketoglutarate (3). Based on homology, both humans and mice contain at least 30 such proteins, which can be divided into 7 separate families (3). The JARID (Jumonji/AT-rich interactive domain-containing protein) family contains four members: JARID1A (also RBP2 and RBBP2), JARID1B (also PLU-1), JARID1C (also SMCX) and JARID1D (also SMCY) (4). In addition to the JmJC domain, these proteins contain JmJN, BRIGHT, C5HC2 zinc-finger, and PHD domains, the latter of which binds to methylated histone H3 (Lys9) (4). All four JARID proteins demethylate di- and tri-methyl histone H3 Lys4; JARID1B also demethylates mono-methyl histone H3 Lys4 (5-7). JARID1A is a critical RB-interacting protein and is required for Polycomb-Repressive Complex 2 (PRC2)-mediated transcriptional repression during ES cell differentiation (8). A JARID1A-NUP98 gene fusion is associated with myeloid leukemia (9). JARID1B, which interacts with many proteins including c-Myc and HDAC4, may play a role in cell fate decisions by blocking terminal differentiation (10-12). JARID1B is over-expressed in many breast cancers and may act by repressing multiple tumor suppressor genes including BRCA1 and HOXA5 (13,14). JARID1C has been found in a complex with HDAC1, HDAC2, G9a and REST, which binds to and represses REST target genes in non-neuronal cells (7). JARID1C mutations are associated with X-linked mental retardation and epilepsy (15,16). JARID1D is largely uncharacterized.

1. Kubicek, S. et al. (2006) Ernst Schering Res Found Workshop , 1-27.
2. Lin, W. and Dent, S.Y. (2006) Curr Opin Genet Dev 16, 137-42.
3. Klose, R.J. et al. (2006) Nat Rev Genet 7, 715-27.
4. Benevolenskaya, E.V. (2007) Biochem Cell Biol 85, 435-43.
5. Christensen, J. et al. (2007) Cell 128, 1063-76.
6. Yamane, K. et al. (2007) Mol Cell 25, 801-12.
7. Tahiliani, M. et al. (2007) Nature 447, 601-5.
8. Pasini, D. et al. (2008) Genes Dev 22, 1345-55.
9. van Zutven, L.J. et al. (2006) Genes Chromosomes Cancer 45, 437-46.
10. Secombe, J. et al. (2007) Genes Dev 21, 537-51.
11. Barrett, A. et al. (2007) Int J Cancer 121, 265-75.
12. Dey, B.K. et al. (2008) Mol Cell Biol 28, 5312-27.
13. Barrett, A. et al. (2002) Int J Cancer 101, 581-8.
14. Lu, P.J. et al. (1999) J Biol Chem 274, 15633-45.
15. Tzschach, A. et al. (2006) Hum Mutat 27, 389.
16. Jensen, L.R. et al. (2005) Am J Hum Genet 76, 227-36.

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM
NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C.
Do not aliquot the antibody.